AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
KORU Medical Systems to Release Q2 2025 Financial Results on August 6, 2025.
ByAinvest
Sunday, Jul 20, 2025 12:56 am ET1min read
KORU Medical Systems plans to release Q2 2025 financial results on August 6, 2025. The company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update. Investors can dial (877)-407-0784 or (201)-689-8560 to join the conference call, while a live and archived webcast will be available on the company's website.
Mahwah, N.J., July 2, 2025 – KORU Medical Systems, Inc. (NASDAQ: KRMD), a leading medical technology company, has announced that it will release its second quarter 2025 financial results on Wednesday, August 6, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update.Investors and analysts can join the conference call by dialing (877)-407-0784 for participants in the U.S. or Canada, and (201)-689-8560 for international callers. A live and archived webcast of the event will be available via the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com. The archived webcast will be available for six months.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions. The company’s flagship product, the Freedom Syringe Infusion System (Freedom System), includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by patients and delivery in ambulatory infusion centers by healthcare professionals. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and can customize the Freedom System for clinical and commercial use across multiple drug categories.
References:
[1] https://www.stocktitan.net/news/KRMD/koru-medical-systems-to-report-second-quarter-2025-financial-results-rx4j6qhlwwkn.html
[2] https://finance.yahoo.com/news/koru-medical-systems-report-second-200500243.html
[3] https://www.barchart.com/story/news/33447505/koru-medical-systems-to-report-second-quarter-2025-financial-results-on-august-6-2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet